Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Lightlake enters into license agreement with Adapt Pharma Operations Lightlake Therapeutics, a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced that it has entered into a license agreement with Adapt Pharma Operations, a wholly owned subsidiary of Adapt Pharma Limited, an Ireland-based pharmaceutical company.
Contract Research & Services > Contract Services > News
DURECT grants worldwide rights of SABER ophthalmology product to Santen By PBR Staff Writer
US-based DURECT has granted exclusive worldwide rights to Santen Pharmaceutical to develop and commercialize a sustained release product using the former's SABER technology to deliver an ophthalmology drug.
Contract Research & Services > Contract Services > News Sorrento, Nantworks to jointly develop next generation cancer immunotherapies By PBR Staff Writer
US-based oncology firm Sorrento Therapeutics has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr Patrick Soon-Shiong.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Sorrento, Nantworks to jointly develop next generation cancer immunotherapies
By PBR Staff Writer
US-based oncology firm Sorrento Therapeutics has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr Patrick Soon-Shiong.
Contract Research & Services > Contract Services > News
Pfizer to develop and commercialize OPKO's long-acting human growth hormone
By PBR Staff Writer
Pfizer and OPKO Health have entered into a partnership to develop and commercialize OPKO’s long-acting hGH-CTP, a growth-hormone deficiency treatment that would require a single weekly injection instead of the current standard of daily injections.
Contract Research & Services > Contract Services > News
Quality of Steel
| By Natoli Engineering Company
Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
Contract Research & Services > Contract Services > White Papers
First Impressions: Tablet Shape Can Impact Patient Acceptance
| By Natoli Engineering Company
First impressions are everything. This is especially true for pharmaceutical, nutritional and confectionery tablets. Discriminating consumers may decide if they will be repeat customers based on a tablet’s appearance and their experience with it. This article discusses the limitations of the flat faced bevel edge and the benefits of a flat faced radius edge tablet design.
Contract Research & Services > Contract Services > White Papers
Array BioPharma grants license to Oncothyreon for ONT-380
By PBR Staff Writer
Array BioPharma (ARRY) has granted an exclusive license to US-based biopharmaceutical firm Oncothyreon for the development, manufacturing and commercialization of ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor.
Contract Research & Services > Contract Services > News
iTeos enters into license and collaboration deal with Pfizer
iTeos Therapeutics announced a strategic collaboration with Pfizer pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2).
Contract Research & Services > Contract Services > News
NovaBay signs distribution agreement with the Biopharm Group
NovaBay Pharmaceuticals, a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, has signed an exclusive distribution agreement for NovaBay’s NeutroPhase Skin and Wound Cleanser with the Biopharm Group, a leading pharmaceutical company in the Middle East, headquartered in Cairo, Egypt.
Contract Research & Services > Contract Services > News
Astellas to end license agreement with Janssen for ASP015K inhibitor
By PBR Staff Writer
Astellas Pharma will end its license agreement with Janssen Biotech to develop and commercialize ASP015K inhibitor on 15 January 2015.
Contract Research & Services > Contract Services > News
Alizé Pharma acquires exclusive worldwide rights on new peptide to tackle bone diseases
By PBR Staff Writer
Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announced that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250